Maria Suarez-Almazor
Overview
Explore the profile of Maria Suarez-Almazor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
2215
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chanson N, Galvagni A, Ramos-Casals M, Ruiz J, Suijkerbuijk K, Benesova K, et al.
Rheumatology (Oxford)
. 2024 Dec;
PMID: 39714261
Objective: To describe presentation, treatment and outcome of immune checkpoint inhibitor (ICI) associated-vasculitis in cancer patients in a multicentre study. Methods: Thanks to the ImmunoCancer International Registry (ICIR), a multidisciplinary...
2.
Qureshi S, Arani N, Parvathareddy V, Tchakarov A, Abdelrahim M, Suarez-Almazor M, et al.
Front Nephrol
. 2023 Sep;
3:1168614.
PMID: 37675380
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer. ICIs have a unique side effect profile, generally caused by inflammatory tissue damage, with clinical features similar to autoimmune conditions....
3.
Flores-Chavez A, Brito-Zeron P, Retamozo S, Bitoun S, Fisher B, Liew D, et al.
Crit Rev Immunol
. 2023 Apr;
42(4):21-36.
PMID: 37022357
Immunotherapies, such as immune checkpoint inhibitors (ICIs), have significantly advanced the treatment of cancer and other conditions. However, these therapies can also cause immune-related adverse events (irAEs), which are unintended...
4.
Ghosh N, Couette N, van Binsbergen W, Weinmann S, Jivanelli B, Shea B, et al.
Semin Arthritis Rheum
. 2022 Nov;
58:152110.
PMID: 36372016
Introduction: Immune checkpoint inhibitors (ICI), increasingly used cancer therapeutics, can cause off-target inflammatory effects called immune-related adverse events (irAEs), including ICI-induced inflammatory arthritis (ICI-induced IA) and polymyalgia rheumatica (ICI-induced PMR)....
5.
Suarez-Almazor M, Pinnix C, Bhoo-Pathy N, Lu Q, Sedhom R, Parikh R
Med
. 2022 May;
2(8):885-888.
PMID: 35590162
While new therapies and techniques offer improved outcomes for individuals with cancer, it is equally important to preserve their physical, social, functional, and emotional well-being. Here, a series of expert...
6.
Schneider B, Naidoo J, Santomasso B, Lacchetti C, Adkins S, Anadkat M, et al.
J Clin Oncol
. 2021 Nov;
39(36):4073-4126.
PMID: 34724392
Purpose: To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitor (ICPi) therapy. Methods: A multidisciplinary...
7.
Santomasso B, Nastoupil L, Adkins S, Lacchetti C, Schneider B, Anadkat M, et al.
J Clin Oncol
. 2021 Nov;
39(35):3978-3992.
PMID: 34724386
Purpose: To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with chimeric antigen receptor (CAR) T-cell therapy. Methods: A...
8.
Alfano C, Suarez-Almazor M, Rodriguez M, Palos G, Gilmore K
J Natl Cancer Inst Monogr
. 2021 Sep;
2021(57):3-9.
PMID: 34478510
New models of survivorship care are needed that improve outcomes for the growing number of cancer survivors, address the increasing complexity of their health needs, and deal with the shortage...
9.
Rodriguez M, Suarez-Almazor M, Palos G
J Natl Cancer Inst Monogr
. 2021 Sep;
2021(57):1-2.
PMID: 34478506
No abstract available.
10.
Lu H, Lei X, Zhao H, Elting L, Siricilla M, Ursani M, et al.
J Bone Miner Res
. 2021 Jan;
36(5):861-871.
PMID: 33484602
Women with estrogen receptor-positive breast cancer who receive an aromatase inhibitor (AI) are at risk for fractures. We aim to determine if dual-energy X-ray absorptiometry (DXA) scans made at the...